Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P00326

UPID:
ADH1G_HUMAN

ALTERNATIVE NAMES:
Alcohol dehydrogenase subunit gamma

ALTERNATIVE UPACC:
P00326; Q4PJ18; Q5WRV0; Q6LBW4; Q6NWV0; Q6NZA7

BACKGROUND:
The enzyme Alcohol dehydrogenase 1C, alternatively named Alcohol dehydrogenase subunit gamma, plays a major role in the metabolism of ethanol, facilitating its oxidation. This highlights its importance in the body's ability to process alcoholic substances.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Alcohol dehydrogenase 1C offers a pathway to innovative therapeutic approaches. Given its significant involvement in ethanol catabolism, it holds promise for addressing alcohol-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.